Tradestie Institutional Equity Comparison Engine

TDOC vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TDOC Overall Edge

TDOC Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Teladoc Health, Inc. (TDOC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, TDOC trades at N/M Forward P/E with -5.4% operating margin (-3.4% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, TDOC sits in CONSOLIDATION (40th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
TDOC N/M vs CRSP 23.4x Fwd P/E
Growth & Margin Winner TDOC
Op Margin -5.4% vs -2058.6% ยท YoY -3.4% vs +1325.1%
Momentum & Technical Winner TDOC
1Y +21.4% vs -20.5% ยท 52W Pos 76% vs 1%
Options & Structure Winner TDOC
CONSOLIDATION (40th %ile IV) vs BREAKDOWN (52nd %ile IV)
TDOC NYSE
Teladoc Health, Inc.
Services-Offices & Clinics Of Doctors Of Medicine
$8.59
-2.44% 1D
Market Cap $1.6B
1M Return +51.41%
1Y Return +21.43%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 24.0 Fund 41.0 Flow 58.0 Mom 60.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TDOC +21.43% CRSP -20.54% Spread: +41.97 pp (TDOC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period TDOC Revenue CRSP Revenue TDOC Op. Margin CRSP Op. Margin Margin Edge
FY2018 $420M $0M -17.0% -5087.8% TDOC
FY2019 $550M $290M -14.5% 16.1% CRSP
FY2020 $1.09B $0M -46.3% -49295.5% TDOC
FY2021 $2.03B $910M -13.1% 40.8% CRSP
FY2022 $2.41B $0M -567.3% -56190.4% TDOC
FY2023 $2.60B $370M -9.6% -60.0% TDOC
FY2024 $2.57B $40M -39.7% -1250.4% TDOC
FY2025 $2.53B $0M -10.4% -18933.6% TDOC

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TDOC (3) vs CRSP (7)
Institutional Metric TDOC CRSP Criterion Row Winner
Market Capitalization Scale $1.6B $4.1B Larger Scale CRSP
Trailing P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio Valuation N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY) Growth -3.4% +1325.1% Higher Growth CRSP
Operating Margin (TTM) Profitability -5.4% -2058.6% Higher Margin TDOC
Net Profit Margin Profitability -6.3% 0.0% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -11.5% -25.6% Higher ROE TDOC
52-Week Range Position Momentum 76% ($4โ€“$10) 1% ($40โ€“$63) Stronger Trend TDOC
Beta / 30D Volatility Risk Regime 0.83ฮฒ ยท 108% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TDOC vs CRSP Buy Guide
TDOC CONSOLIDATION
93d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 40th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live TDOC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TDOC nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.